Effects of glycoprotein IIb/IIIa inhibitors in patients undergoing percutaneous coronary intervention after pretreatment with clopidogrel: A meta-analysis of randomized trials

Critical Pathways in Cardiology

Volumn 7, Issue 1, 2008, Pages 5-10

  Pannu, Rajmony ^a   Andraws, Richard ^b  

^a NEW HANOVER REGIONAL MEDICAL CENTER   (United States)

^b SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

Abciximab; Clopidogrel; Percutaneous coronary intervention; Tirofiban

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; TIROFIBAN; DRUG DERIVATIVE; FIBRINOGEN RECEPTOR; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY; TICLOPIDINE;

ACUTE CORONARY SYNDROME; ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY BYPASS SURGERY; CORONARY STENT; DRUG EFFICACY; DRUG SAFETY; HEART INFARCTION; HUMAN; LOADING DRUG DOSE; META ANALYSIS; MORBIDITY; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION; SYSTEMATIC REVIEW; THROMBOSIS; AGED; ANGIOCARDIOGRAPHY; CONFIDENCE INTERVAL; CORONARY ARTERY DISEASE; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG ANTAGONISM; DRUG COMBINATION; FEMALE; MALE; METHODOLOGY; PROGNOSIS; RADIOGRAPHY; REVIEW; RISK; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; CONFIDENCE INTERVALS; CORONARY ANGIOGRAPHY; CORONARY DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; ODDS RATIO; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 47149083100     PISSN: 1535282X     EISSN: 15352811     Source Type: Journal    
DOI: 10.1097/HPC.0b013e318163ebc9     Document Type: Article

References (30)

1. Kereiakes DJ, Michelson AD.Platelet activation and progression to complications.Rev Cardiovasc Med.2006;7:75-81.
2. Gurbel PA.The relationship of platelet reactivity to the occurrence of post-stenting ischemic events: emergence of a new cardiovascular risk factor.Rev Cardiovasc Med.2006;7(suppl 4):S20-S28.
3. Steinhubl SR, Berger PB, Mann JT III, et al.Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized clinical trial.JAMA.2002;288:2411-2420.
4. Mehta SM, Yusuf S, Peters RGJ, et al.Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.Lancet.2001;358:527-533.
5. Boersma E, Harrington RA, Moliterno DJ, et al.Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomized clinical trials.Lancet.2002;359:189-198.
6. Lincoff AM, Califf RM, Topol EJ.Platelet glycoprotein IIb/IIIa blockade in coronary artery disease.J Am Coll Cardiol.2000;35:1103-1115.
7. Kelly RV, Steinhubl S.Changing roles of anticoagulant and antiplatelet treatment during percutaneous coronary intervention.Heart.2005;91(suppl III):iii16-iii19.
8. Claeys MJ, Van der Planken MG, Bosmans JM, et al.Does pretreatment with clopidogrel obviate the need for glycoprotein IIb/IIIa antagonists during elective coronary stenting? A focus on peri-procedure myone-crosis.Eur Heart J.2005;26:567-575.
9. Steinhubl SR, Charnigo R.Clopidogrel pretreatment prior to percutane ous coronary intervention: when enough isn't enough.JAMA.2006;295:1581-1582.
10. Alexander KP, Chen AY, Roe MT, et al.Excess dosing of antiplatelet nd antithrombin agents in the treatment of non-ST-segment elevation cute coronary syndromes.JAMA.2005;294:3108-3116.
11. Meade MO, Richardson WS.Selecting and appraising studies for a ystematic review.Ann Intern Med.1997;127:531-537.
12. Schulz KF, Chalmers I, Hayes RJ, et al.Empirical evidence of bias:dimensions of methodologic quality associated with estimates of treatment effects in controlled trials.JAMA.1995;273:408 -412.
13. Dersimonian R, Laird N.Meta-analysis in clinical trials.Control Clin rials.1986;7:177-188.
14. Higgins JPT, Thompson SG, Deeks JJ, et al.Measuring inconsistency in eta-analysis.BMJ.2003;327:557-560.
15. Rasoul S, Ottervanger JP, de Boer MJ, et al.A comparison of dual vs.triple antiplatelet therapy in patients with non-ST-segment elevation cute coronary syndrome: results of the ELISA-2 trial.Eur Heart J.2006;27:1401-1407.
16. Kastrati A, Mehilli J, Neumann FJ, et al.Abciximab in patients with cute coronary syndromes undergoing percutaneous coronary interven on after clopidogrel pretreatment: the ISAR-REACT 2 randomizedtrial.JAMA.2006;295:1531- 1538.
17. Bonz AW, Lengenfelder B, Strotmann J, et al.Effect of additional emporary glycoprotein IIb/IIIa receptor inhibitor inhibition on troponin elease in elective percutaneous coronary intervention after pretreatment ith clopidogrel (TOPSTAR trial).J Am Coll Cardiol.2002;40:662-668.
18. Mehilli J, Kastrati A, Schuhlen H, et al.Randomized clinical trial of bciximab in diabetic patients undergoing elective percutaneous coro ary interventions after treatment with a high loading dose of clopi-dogrel. Circulation.2005;110:3627-3635.
19. Kastrati A, Mehilli J, Schuhlen H, et al.A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment withclopidogrel.N Engl JMed.2004;350:232-238.
20. Schomig A, Schmitt C, Dibra A, et al.One year outcomes with abciximab vs.placebo during percutaneous coronary intervention afterpre-treatment with clopidogrel.Eur Heart J.2005;26:1379 -1384.
21. Longstreth KL, Wertz JR.High-dose clopidogrel loading in percutaneous coronary intervention.Ann Pharmacother.2005;39:918 -922.
22. Ellis SG, Vandormael MG, Cowley MJ, et al.Multivessel angioplasty prognosis study group.Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease: implication for participant selection.Circulation.1990;82:1193-1202.
23. Brown DL, Fann CS, Chang CJ.Effect of glycoprotein IIb/IIIa inhibitors on the individual components of composite endpoints used in clinical trials of unstable angina and non-Q-wave myocardial infarction.Car diovasc Drugs Ther.2000;14:253-258.
24. Quinn MJ, Bhatt DL, Zidar F, et al.Effect of clopidogrel pretreatment on inflammatory marker expression in patients undergoing percutaneouscoronary intervention.Am J Cardiol.2004;93:679-684.
25. Dalby M, Montalescot G, Bal dit Sollier C, et al.Eptifibatide provides additional platelet inhibition in non-ST-elevation myocardial infarction patients already treated with aspirin and clopidogrel: results of the platelet activity extinction in non-Q-wave myocardial infarction with aspirin, clopidogrel, and eptifibatide (PEACE) study.J Am Coll Cardiol.2004;43:162-168.
26. Gurbel PA, Bliden KP, Zaman KA, et al.Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the clopidogrel loading with eptifibatide to arrest the reactivity of platelets (CLEAR PLATELETS) study.Circulation.2005;111:1153-1159.
27. Topol EJ, Byzova TV, Plow EF.Platelet GP IIb-IIIa blockers.Lancet. 1999;353:227-231.
28. Duffy B, Bhatt DL.Antiplatelet agents in patients undergoing percutaneous coronary intervention: how many and how much? Am J Cardio vasc Drugs.2005;5:307-318.
29. Ferreira-Gonzalez I, Permanyer-Miralda G, Domingo-Salvany A, et al.Problems with use of composite end points in cardiovascular trials:systematic review of randomised controlled trials.BMJ.2007;334:786-792.
30. Pregowski J, Witkowski A, Sitkiewicz D.Significance of aspirin and clopidogrel resistance in patients undergoing percutaneous coronary interventions.Curr Vasc Pharmacol.2007;5:135-140.